Ozempic and Wegovy, used for diabetes and weight loss, show a link to NAION, a rare eye disorder causing blindness. A study found semaglutide users had a higher risk. Diabetes patients had a four-fold increase, while weight loss patients had a seven-fold increase in risk. Researchers advise caution, not discontinuation, of these medications.
